Synta Pharmaceuticals Corp. Share Price Nasdaq
Equities
US87162T2069
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2024 * | 81.74M 6.82B | Sales 2025 * | 351M 29.33B | Capitalization | 4.89B 408B |
---|---|---|---|---|---|
Net income 2024 * | -459M -38.29B | Net income 2025 * | -296M -24.7B | EV / Sales 2024 * | 58.7 x |
Net cash position 2024 * | 93.53M 7.8B | Net Debt 2025 * | 116M 9.7B | EV / Sales 2025 * | 14.2 x |
P/E ratio 2024 * |
-9.87
x | P/E ratio 2025 * |
-15.5
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.92% |
Latest transcript on Synta Pharmaceuticals Corp.
Managers | Title | Age | Since |
---|---|---|---|
Edward Chiang
FOU | Founder | - | 01/11/01 |
William Sibold
CEO | Chief Executive Officer | - | 08/23/08 |
Rebecca Taub
FOU | Founder | 71 | 01/16/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 78 | 01/11/01 | |
Julian Baker
CHM | Chairman | 57 | 15/23/15 |
Ken Bate
BRD | Director/Board Member | 73 | 22/16/22 |
1st Jan change | Capi. | |
---|---|---|
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |